TrialPath
Recruiting

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614 · Children's Oncology Group
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multi-Institutional Central Pathology and Molecular Risk-Based Stratification Study of Surgical Management for Melanoma, Atypical Spitz/Spitzoid Tumors, and Other Atypical Melanocytic Neoplasms in Pediatric Patients
About this study
PRIMARY OBJECTIVE: I. To study the feasibility of central risk-based stratification of malignant and atypical cutaneous melanocytic tumors to guide primary surgical management. SECONDARY OBJECTIVES: I. To evaluate the adherence rate to protocol-assigned surgical management in children with newly diagnosed melanoma, atypical Spitz/Spitzoid tumors, and other atypical melanocytic neoplasms. II. To evaluate the surgery-related adverse events profile for patients treated with narrow re-excision without sentinel lymph node biopsy versus wide local excision +/- sentinel lymph node biopsy per standard adult cutaneous melanoma guidelines. III. To describe progression free survival (PFS) and overall survival (OS) in pediatric patients with melanoma, atypical Spitz/Spitzoid tumors, and other atypical melanocytic neoplasms. EXPLORATORY OBJECTIVES: I. To describe surgical reconstruction techniques for pediatric patients with atypical and malignant melanocytic tumors. II. To describe the use of sentinel lymph node biopsy and rate of completion nodal dissection vs observation following positive sentinel lymph node including number of sentinel nodes sampled, size of largest metastatic nodal deposit, location of draining lymph node basin(s), number of lymph nodes resected at completion dissection. III. To describe surgical complications of completion nodal dissection (from time of surgery to 90 days following surgery): wound dehiscence, seroma/hematoma, hemorrhage, infection, skin graft failure, necrosis of flap used for reconstruction, lymphocele, lymphedema, deep vein thrombosis. IV. To evaluate the concordance between local treating center pathologic diagnosis and central pathology review diagnosis. V. To analyze the molecular characterization of melanocytic tumors to identify molecular and immunohistochemical biomarkers correlating with known clinical prognostic factors and outcome. VI. To determine the number of Children's Oncology Group (COG) institutions that open the study within 18 months of activation. OUTLINE: Patients with not atypical pathology are assigned to the Observation Arm. Patients with atypical low-risk tumors are assigned to Treatment Arm A and patients with atypical high-risk tumors are assigned to Treatment Arm B. OBSERVATION ARM: Patients undergo observation throughout the study. TREATMENT ARM A: Patients may undergo narrow margin re-excision without sentinel lymph node biopsy. After completion of study intervention, patients are followed every 6 months for 1 year then every year for up to 5 years. TREATMENT ARM B: Patients undergo wide local excision with or without sentinel lymph node biopsy (SLNB) per standard guidelines. Patients may also undergo blood sample collection, chest x-ray, computed tomography (CT), magnetic resonance imaging (MRI), whole-body fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/CT or PET/MRI, nodal basin ultrasound, and brain MRI on study. After completion of study treatment, patients are followed every 3-6 months for years 1 and 2, every 6 months up to year 5.
Eligibility criteria
Inclusion Criteria: * Patients ≤ 25 years old * Newly diagnosed localized cutaneous melanoma, atypical Spitz/Spitzoid tumors, or other atypical melanocytic neoplasm by local institution pathology report * Patients must have disease that is localized to the skin on clinical assessment. Note that staging imaging is not required for the determination of eligibility, but if obtained prior to enrollment, all imaging must be consistent with localized cutaneous disease * Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age * Patients must not have received any prior chemotherapy, immunotherapy, targeted therapy, radiation, or surgical therapy for melanoma other than the permitted biopsy/excision of the lesion for which they are enrolling. Note that prior biopsies/surgery for other benign melanocytic lesions is permitted Exclusion Criteria: * Patients ≥ 18 years old with conventional adult-type melanoma are excluded. Note that patients 18-25 years old with atypical Spitz/Spitzoid tumors, or other atypical melanocytic neoplasms are eligible * Patients with clinical evidence of metastatic disease such as palpable malignant adenopathy or symptomatic distant metastases are not eligible * Patients who have undergone re-excision to achieve a negative margin or sentinel lymph node biopsy for the melanocytic neoplasm under study are not eligible. Note that this does not exclude patients who have undergone the permitted diagnostic biopsy/excision, including re-biopsy, of the lesion * Any of the following diagnoses * Congenital nevi-associated proliferative nodules * Agminated Spitz nevi/tumors * Dysplastic nevus * Combined nevus * CRTC1::TRIM11 and/or MED15::ATF1 fused tumors (molecular testing is not required prior to enrollment) * Pre-existing conditions: * Solid organ transplant recipients * Known melanoma predisposition syndrome (i.e., patients with previously known pathogenic variants in moderate and high penetrance melanoma susceptibility genes \[i.e., CDKN2A, CDK4, BAP1, POT1, TERT promoter, ACD, TERF2IP\] or Xeroderma Pigmentosum). Note germline testing is not required prior to enrollment * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Study design
Enrollment target: 51 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult
Timeline
Starts: 2027-05-15
Estimated completion: 2028-07-31
Last updated: 2026-09-24
Interventions
Procedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Computed TomographyOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyProcedure: Re-ExcisionProcedure: Sentinel Lymph Node BiopsyProcedure: Ultrasound ImagingProcedure: Wide Local Excision
Primary outcomes
  • • Feasibility success rate (Within 8 weeks of enrollment)
Sponsor
Children's Oncology Group · network
Contacts & investigators
InvestigatorBrittani K Seynnaeve · principal_investigator, Children's Oncology Group
All locations (13)
Kaiser Permanente-OaklandRecruiting
Oakland, California, United States
Alfred I duPont Hospital for ChildrenRecruiting
Wilmington, Delaware, United States
Nemours Children's Clinic-JacksonvilleRecruiting
Jacksonville, Florida, United States
Nemours Children's HospitalRecruiting
Orlando, Florida, United States
Nemours Children's Clinic - PensacolaRecruiting
Pensacola, Florida, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's HospitalRecruiting
Toledo, Ohio, United States
Children's Hospital of PhiladelphiaRecruiting
Philadelphia, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMCRecruiting
Pittsburgh, Pennsylvania, United States
East Tennessee Childrens HospitalRecruiting
Knoxville, Tennessee, United States
Saint Jude Children's Research HospitalRecruiting
Memphis, Tennessee, United States
Dell Children's Medical Center of Central TexasRecruiting
Austin, Texas, United States
UT MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
Primary Children's HospitalRecruiting
Salt Lake City, Utah, United States
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information · TrialPath